Xspray Pharma AB (publ) (6XP.SG)
- Previous Close
3.0800 - Open
2.8950 - Bid 3.0100 x --
- Ask 3.2000 x --
- Day's Range
2.8950 - 2.8950 - 52 Week Range
2.1550 - 7.6300 - Volume
0 - Avg. Volume
0 - Market Cap (intraday)
107.516M - Beta (5Y Monthly) 0.64
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6900 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer; and XS025, a amorphous non-crystalline cabozantinib for the treatment of renal cell carcinoma and other cancers. It has partnership agreements with EVERSANA for the commercialization of Dasynoc, as well as with NerPharMa S.r.l for production of Dasynoc. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is headquartered in Solna, Sweden.
www.xspraypharma.comRecent News: 6XP.SG
View MorePerformance Overview: 6XP.SG
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6XP.SG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6XP.SG
View MoreValuation Measures
Market Cap
108.98M
Enterprise Value
109.10M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.16
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.67%
Return on Equity (ttm)
-43.38%
Revenue (ttm)
2.1M
Net Income Avi to Common (ttm)
-285.52M
Diluted EPS (ttm)
-0.6900
Balance Sheet and Cash Flow
Total Cash (mrq)
208.24M
Total Debt/Equity (mrq)
20.58%
Levered Free Cash Flow (ttm)
-177.16M